US denying emergency approval to Covaxin will have no impact on our vaccine programme: Govt

By: |
June 11, 2021 7:35 PM

In what could potentially delay the launch of Covaxin in the US, the Food and Drug Administration there has “recommended” Ocugen Inc, the US partner of the Indian vaccine maker, to go for Biologics Licence Application (BLA) route with additional data, nixing hopes of emergency use authorisation.

Suchitra Ella said the data of Phase 3 trials has been submitted to the Drug Controller General of India for its perusal and efficacy of the vaccine against many of the coronavirus variants was also tested.Suchitra Ella said the data of Phase 3 trials has been submitted to the Drug Controller General of India for its perusal and efficacy of the vaccine against many of the coronavirus variants was also tested.

In the view of the US FDA rejecting emergency use authorisation to Bharat Biotech’s Covaxin, the government Friday said it respects the decision but asserted it will have no impact whatsoever on India’s vaccination programme.

In what could potentially delay the launch of Covaxin in the US, the Food and Drug Administration there has “recommended” Ocugen Inc, the US partner of the Indian vaccine maker, to go for Biologics Licence Application (BLA) route with additional data, nixing hopes of emergency use authorisation.

Responding to a question on the denial to Covaxin, NITI Aayog member (Health) V K Paul said each country has its own regulatory system which India respects and hoped that the manufacturer will be able to comply with it by doing whatever requires to be done.

“Each country has its own regulatory system. Some parameters might be common while some might be different which we respect. Our country’s regulatory system also takes decisions in a similar manner. The scientific framework is the same but nuancing is on context… These are scientific considerations specially in those countries where science is strong and for us manufacturing is strong,” he said.

“We expect that our manufacturer will be able to comply with it by doing whatever requires to be done. It will have no impact whatsoever on our programme clearly. We are satisfied our regulator has approved it. We have so much data on safety and so much data on phase-3 trial that has been screened by them,” Paul added.

He further said that the phase 3 publication of Covaxin will also come in 7-8 days which is beyond data shared with DCGI.

“We are doing very well. We respect their decision but it will have no bearing on our track at this moment,” he added.

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, Check out latest IPO News, Best Performing IPOs, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

Next Stories
1Coronavirus December 1 Live News: India reports 8,954 new Covid-19 cases, 267 deaths; Active cases drop below 1 lakh for first time since June 3 last year
2No Omicron cases in India yet, says health minister Mansukh Mandaviya
3Covid related restrictions extended in Bengal till Dec 15